Omentin-1 vs Adiponectin
Head-to-head comparison of Omentin-1 (Omentin-1 (Intelectin-1, ITLN1)) and Adiponectin (Adiponectin (Acrp30, AdipoQ)) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Omentin-1 | Adiponectin |
|---|---|---|
| Category | Diabetes & Metabolic | Diabetes & Metabolic |
| Full Name | Omentin-1 (Intelectin-1, ITLN1) | Adiponectin (Acrp30, AdipoQ) |
| Molecular Weight | ~35 kDa | ~26.4 kDa (monomer) |
| Half-Life | hours | ~2-4 h |
| Amino Acids | 313 | 244 |
| Typical Dose | No approved human dose; research use only | No approved human dose; research use only |
| Route | IV|SC | IV|SC |
| Purity | ≥98% | ≥98% |
| Studies Count | 82 | 86 |
| Research Status | Pre-clinical | Pre-clinical |
Omentin-1 Benefits
- ✓insulin sensitivity
- ✓glucose uptake
- ✓lipid handling
Adiponectin Benefits
- ✓insulin sensitivity
- ✓fatty-acid oxidation
- ✓AMPK activation
Omentin-1 Dosing
not established|not established
Adiponectin Dosing
not established|not established
Omentin-1 Side Effects
- ⚠unknown
- ⚠immunogenicity risk
Adiponectin Side Effects
- ⚠unknown
- ⚠immunogenicity risk
Research Overview
Omentin-1
Lower omentin-1 levels are often associated with obesity, insulin resistance, and metabolic syndrome. Research continues on its use as a biomarker and as a mechanistic lead for AMPK-linked metabolic interventions.
Adiponectin
Preclinical and translational studies link adiponectin signaling with better glycemic control, lower inflammation, and improved lipid handling. Recombinant adiponectin and receptor-targeting approaches remain research tools rather than approved diabetes therapies.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.